AI Stock Monitor
JNJ - Johnson & Johnson
Johnson & Johnson is a North America covered company in The Hedge Book research universe.
Public company · North America · Healthcare · Pharmaceuticals · Medical Devices · Dow constituent
0 followers · Follow to include this stock in your daily 9:30 AM Central watchlist email.
NYSE · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score
70
/100
Price History
JNJ chart
AI-Assisted Chart Analysis
Johnson & Johnson technical analysis
Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.
Constructive uptrend: the latest level is above the 50-period average and the 50-period average is above the 200-period average.
RSI is 62, a neutral reading. Above 70 can signal extension; below 30 can signal exhaustion.
The first technical watch zone is 253.04. A break below 179.71 invalidates the near-term support setup.
The first resistance/watch zone is 279.11. A confirmed break above 279.11 supports continuation.
Annualized realized volatility is +39.9%. Maximum lookback drawdown is -22.1%, from a high-water mark of 182.29 to 142.06.
Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.
How To Read This Stock Brief
Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.
Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.
Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.
This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.
What Changed Today
- Yahoo Finance delayed market data reported JNJ at 279.13 USD; the latest daily move rose +1.05%. This is a verified market-price signal only and does not by itself confirm a change in company fundamentals.
Why It Matters
- The verified +1.05% daily move is current market context for Johnson & Johnson.
- It can affect near-term sentiment, but price action alone does not establish a change in earnings, asset quality, competitive position, valuation, catalysts, or risks.
- Those require a separately sourced filing or company update.
AI Opinion
- Read: The signal is Bullish, driven by a high-frequency cadence of positive clinical and regulatory developments that de-risk the long-term pipeline.
- Evidence: Evidence of 7.7% growth in the Innovative Medicine unit provides tangible proof of operational health, countering bearish narratives regarding patent cliffs.
- Uncertainty: However, the 'limited upside' analyst consensus acts as a ceiling, suggesting that investors are already accounting for these successes or are wary of broader valuation compression in the healthcare space.
- Watch: A shift in this view would require either a significant earnings surprise that exceeds current growth expectations or a material change in the regulatory environment that accelerates drug commercialization.
Key Risks
- Persistent analyst concerns regarding limited upside suggest that the market may be fully valuing the current pipeline, leaving little room for error if future clinical data disappoints.
- Regulatory and legal headwinds, including ongoing litigation or pricing pressures, could offset the gains from new drug approvals and dampen margin expansion.
- The company faces long-term revenue risks from patent expirations in its core portfolio, which requires continuous, successful R&D output to maintain current growth rates.
Upcoming Catalysts
- Continued successful commercialization of newly approved therapies like RYBREVANT FASPRO will be essential to translate R&D success into tangible revenue growth.
- Future earnings reports that demonstrate sustained margin expansion in the Innovative Medicine unit would likely force a re-evaluation of the 'limited upside' thesis.
- Further positive data readouts from the late-stage pipeline, particularly for nipocalimab and other high-potential assets, could serve as a catalyst for multiple expansion.
Upcoming Events
No verified update available
Last Updated
Sources and verification
Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.
- Published stock briefSecondary sourceReportedCheck out Johnson & Johnson's stock price (JNJ) in real time - CNBC · Published 2026-11-09 10:04:54Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedSmith & Nephew SNATS Q3 Earnings Call Highlights · Published 2026-11-09 10:04:54Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedJohnson & Johnson (JNJ): Limited Analyst Upside, but Management Sees a Clearer Path to Growth - Yahoo Finance · Published 2026-11-09 10:04:54Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedJohnson & Johnson (JNJ): Limited Analyst Upside, but Management Sees a Clearer Path to Growth · Published 2026-11-09 10:04:54Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceAnalyst OpinionJohnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer - Morningstar · Published 2026-11-09 10:04:54Open verification sourceSupports: Published stock brief
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.
Community View
Sign in with Google to vote once per stock.
Total votes: 0
Disclaimer
The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.